| Literature DB >> 35447896 |
Ling Qin1, Hui Xu1, Yingying He1, Chen Liang1, Kai Wang1, Junhan Cao1, Changfeng Qu1,2,3, Jinlai Miao1,2,3.
Abstract
An immunomodulatory polysaccharide (DAP4) was extracted, purified, and characterized from Durvillaea antarctica. The results of chemical and spectroscopic analyses demonstrated that the polysaccharide was a fucoidan, and was mainly composed of (1→3)-α-l-Fucp and (1→4)-α-l-Fucp residues with a small degree of branching at C-3 of (1→4)-α-l-Fucp residues. Sulfate groups were at C-4 of (1→3)-α-l-Fucp, C-2 of (1→4)-α-l-Fucp and minor C-6 of (1→4)-β-d-Galp. Small amounts of xylose and galactose exist in the forms of β-d-Xylp-(1→ and β-d-Gal-(1→. The immunomodulatory activity of DAP4 was measured on RAW 264.7 cells, the results proved that DAP4 exhibited excellent immunomodulatory activities, such as promoted the proliferation of spleen lymphocytes, increased NO production, as well as enhanced phagocytic of macrophages. Besides, DAP4 could also produce better enhancement on the vitality of NK cells. For the high immunomodulatory activity, DAP4 might be a potential source of immunomodulatory fucoidan with a novel structure.Entities:
Keywords: Durvillaea antarctica; fucoidan; immunomodulatory; structural characterization
Mesh:
Substances:
Year: 2022 PMID: 35447896 PMCID: PMC9026115 DOI: 10.3390/md20040223
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 6.085
Figure 1Q Sepharose Fast Flow column, HPLC chromatograms, and IR spectrum of DAP4. (A) The crude polysaccharide was separated by a Q Sepharose Fast Flow column.; (B) monosaccharide composition analysis of DAP4; (C) HPGPC chromatogram of DAP4 and the standard curve of molecular weight; and (D) IR spectrum of DAP4.
Composition analysis of polysaccharide isolated from D. antarctica.
| Sample | Total Sugar | Protein | Sulfate | Mw (kDa) | Monosaccharide Composition (Molar Ratio %) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Man | GlcA | Glc | Gal | Xyl | Fuc | |||||
| DAP | 69.8 | 3.4 | 20.7 | nd | 9.7 | 11.8 | 19.7 | 18.1 | 5.9 | 34.8 |
| DAP1 | 78.2 | 2.1 | 4.5 | 754 | 9.2 | nd a | 82.1 | 3.4 | nd a | 5.3 |
| DAP2 | 76.7 | 1.0 | 15.6 | 532 | 23.5 | 0.9 | 23.7 | 9.5 | 6.8 | 35.6 |
| DAP3 | 82.3 | nd | 17.7 | 368 | 17.8 | 2.3 | 4.3 | 32.1 | 4.2 | 39.3 |
| DAP4 | 75.9 | 0.2 | 22.3 | 92 | 2.9 | 1.2 | nd a | 3.5 | 4.5 | 87.9 |
a not detected.
Methylation analyses of DAP4 and DAP4-Ds.
| Methylate Alditol Acetate | Molar Percent Ratio | Linkage Pattern | |
|---|---|---|---|
| DAP4 | DAP4-Ds | ||
| 1,5-Di-O-acrtyl-2,3,4-tri-O-methyl- | 3.22 | 3.41 | Xyl |
| 1,5-Di-O-acetyl-2,3,4-tri-O-methyl- | 7.68 | 6.42 | Fuc |
| 1,5-Di-O-acetyl-2,3,4,6-tetra-O-methyl- | 1.47 | 1.13 | Gal |
| 1,3,5-Tri-O-acetyl-2,4-di-O-methyl- | 24.73 | 37.92 | →3)-Fuc |
| 1,4,5-Tri-O-acetyl-2,3-di-O-methyl- | 21.42 | 28.23 | →4)-Fuc |
| 1,2,5-Tetra-O-acetyl-3,4-di-O-methyl-fucitol | 5.24 | 7.54 | →2)-Fuc |
| 1,3,4,5-Tetra-O-acetyl-2-O-methyl-fucitol | 24.43 | 12.01 | →3,4)-Fuc |
| 1,2,4,5-Tri-O-acetyl-3-O-methyl- | 8.36 | nd a | →2,4)-Fuc |
| 1,4,5-Tri-O-acetyl-2,3,6-tri-O-methyl- | 2.21 | 3.34 | →4)-Gal |
| 1,4,5,6-Tetra-O-acetyl-2,3-di-O-methyl- | 1.24 | nd a | →4,6)-Gal |
a not detected.
Figure 2NMR spectra of DAP4. Spectra were performed on an Agilent DD2 500 MHz NMR spectrometer using acetone as internal standard. (A) 1H NMR spectrum; (B) 13C spectrum; (C) 1H–1H COSY spectrum; (D) 1H–13C HSQC spectrum; (E) 1H–1H NOESY spectrum. A–H correspond to →4)-α-l-Fucp(2SO4)-(1→, →3)-α-l-Fucp(4SO4)-(1→, →2)-α-l-Fucp-(1→, β-d-Xylp-(1→, →3)-α-l-Fucp-(1→, →3,4)-α-l-Fucp-(1→, →4)-α-l-Fucp-(1→ and β-d-Galp-(1→.
1H and 13C NMR spectral data of DAP4.
| Residue b | Chemical Shifts (ppm) a | |||||
|---|---|---|---|---|---|---|
| H1/C1 | H2/C2 | H3/C3 | H4/C4 | H5/C5 | H6/C6 | |
|
| 5.57/100.08 | 4.64/82.29 | 3.96/73.59 | 4.29/80.21 | 3.90/68.31 | 1.43/17.22 |
|
| 5.50/95.23 | 4.21/76.15 | 4.60/75.76 | 4.71/82.12 | 3.90/68.31 | 1.43/17.22 |
|
| 5.44/97.79 | 4.29/82.29 | 4.11/73.69 | 4.04/70.32 | 3.68/68.31 | 1.43/17.22 |
|
| 5.41/110.16 | 3.85/73.42 | --/-- | --/-- | --/-- | --/-- |
|
| 5.34/99.20 | 4.29/73.59 | 4.11/77.94 | 3.96/74.71 | 3.90/68.31 | 1.30/17.22 |
|
| 5.34/97.79 | 4.29/73.59 | 4.11/77.94 | 4.23/78.32 | 4.01/69.7 | 1.30/17.22 |
|
| 5.16/99.20 | 4.29/73.40 | 4.03/73.59 | 4.34/79.95 | 4.01/69.7 | 1.30/17.22 |
|
| 4.52/104.70 | --/-- | --/-- | --/-- | --/-- | 3.80/62.33 |
a Chemical shifts are referenced to internal acetone. b A–H correspond to →4)-α-l-Fucp(2SO4)-(1→, →3)-α-l-Fucp(4SO4)-(1→, →2)-α-l-Fucp-(1→, β-d-Xylp-(1→, →3)-α-l-Fucp-(1→, →3,4)-α-l-Fucp-(1→, →4)-α-l-Fucp-(1→ and β-d-Galp-(1→.
Figure 3Tentative structure of DAP4 from Durvillaea antarctica.
Figure 4Effects of DAP4 on RAW264.7 cell viability (A), and neutral red phagocytic (B). * p < 0.05, ** p < 0.01 versus the control group.
Figure 5Effects of DAP4 on splenic T lymphocyte proliferation (A), splenic B lymphocyte proliferation (B). * p < 0.05, ** p < 0.01, versus with control group; # p < 0.05, versus the ConA or LPS groups.
Figure 6Effects of DAP4 on (A) NO production of RAW264.7 macrophages, and (B) NK cell viability. All values are expressed as means ± SD of three independent experiments. * p < 0.05. ** p < 0.01 compared with the control group.